Literature DB >> 19428422

Decision making under risk and under ambiguity in Parkinson's disease.

M Delazer1, H Sinz, L Zamarian, H Stockner, K Seppi, G K Wenning, T Benke, W Poewe.   

Abstract

In the present study we investigate decision making under ambiguity and decision making under risk in Parkinson's disease (PD) patients without cognitive impairment and in patients affected by Parkinson's disease dementia (PDD). In decisions under ambiguity, participants are not aware of the rules for gains and losses and have to learn about the utility of their selections through feedback. The two patient groups showed significant deficits and did not differ in the frequency of advantageous choices, though they had a markedly different cognitive profile. In decisions under risk, explicit information on the options' probabilities as well as on the associated gains and losses is given. PD patients and healthy controls performed at the same level, whereas PDD patients made significantly more risky and disadvantageous decisions. Results of the study suggest that both patient groups are impaired in decision making when learning by feedback and emotional processing is required, while only the PDD group shows difficulties when decision making is based on cognitive reasoning strategies.

Entities:  

Mesh:

Year:  2009        PMID: 19428422     DOI: 10.1016/j.neuropsychologia.2009.02.034

Source DB:  PubMed          Journal:  Neuropsychologia        ISSN: 0028-3932            Impact factor:   3.139


  19 in total

1.  Self-reported strategies in decisions under risk: role of feedback, reasoning abilities, executive functions, short-term-memory, and working memory.

Authors:  Johannes Schiebener; Matthias Brand
Journal:  Cogn Process       Date:  2015-08-20

Review 2.  Decision-making cognition in neurodegenerative diseases.

Authors:  Ezequiel Gleichgerrcht; Agustín Ibáñez; María Roca; Teresa Torralva; Facundo Manes
Journal:  Nat Rev Neurol       Date:  2010-10-12       Impact factor: 42.937

Review 3.  Impulsivity and Parkinson's disease: more than just disinhibition.

Authors:  Francesca Antonelli; Nicola Ray; Antonio P Strafella
Journal:  J Neurol Sci       Date:  2011-06-17       Impact factor: 3.181

4.  Executive functioning and risk-taking behavior in Parkinson's disease patients with impulse control disorders.

Authors:  Fanny Pineau; Emmanuel Roze; Lucette Lacomblez; Anne-Marie Bonnet; Marie Vidailhet; Virginie Czernecki; Jean-Christophe Corvol
Journal:  J Neural Transm (Vienna)       Date:  2016-04-16       Impact factor: 3.575

Review 5.  Reward processing in neurodegenerative disease.

Authors:  David C Perry; Joel H Kramer
Journal:  Neurocase       Date:  2014-01-13       Impact factor: 0.881

6.  The Protective Action Encoding of Serotonin Transients in the Human Brain.

Authors:  Rosalyn J Moran; Kenneth T Kishida; Terry Lohrenz; Ignacio Saez; Adrian W Laxton; Mark R Witcher; Stephen B Tatter; Thomas L Ellis; Paul Em Phillips; Peter Dayan; P Read Montague
Journal:  Neuropsychopharmacology       Date:  2018-01-03       Impact factor: 7.853

7.  Decision making and executive functions in REM sleep behavior disorder.

Authors:  Margarete Delazer; Birgit Högl; Laura Zamarian; Johanna Wenter; Laura Ehrmann; Viola Gschliesser; Elisabeth Brandauer; Werner Poewe; Birgit Frauscher
Journal:  Sleep       Date:  2012-05-01       Impact factor: 5.849

8.  Iowa Gambling Task in patients with early-onset Parkinson's disease: strategy analysis.

Authors:  Tomáš Gescheidt; Kristína Czekóová; Tomáš Urbánek; Radek Mareček; Michal Mikl; Radka Kubíková; Sabina Telecká; Hana Andrlová; Ivica Husárová; Martin Bareš
Journal:  Neurol Sci       Date:  2012-04-17       Impact factor: 3.307

Review 9.  Clinical diagnostic criteria and classification controversies in frontotemporal lobar degeneration.

Authors:  Katya Rascovsky; Murray Grossman
Journal:  Int Rev Psychiatry       Date:  2013-04

10.  Functional anatomy of outcome evaluation during Iowa Gambling Task performance in patients with Parkinson's disease: an fMRI study.

Authors:  Tomáš Gescheidt; Radek Mareček; Michal Mikl; Kristína Czekóová; Tomáš Urbánek; Jiří Vaníček; Daniel J Shaw; Martin Bareš
Journal:  Neurol Sci       Date:  2013-04-23       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.